Paris, 22nd September 2016 – Bryan, Garnier & Co advised Spineart, the medical device company focused on orthopaedic surgery, on a €30m equity investment from Gimv, a healthcare specialist investor. Within the context of the financing process, led by Bryan, Garnier & Co, the bank raised interest from leading international investors. Gimv was chosen from amongst these investors for its ability to fully respond to Spineart’s ambitions: to accelerate its expansion in Europe and the US, penetrate new markets and develop its R & D projects.
an aging population, economic development in emerging countries and lifestyles
with an increasing number of risks, the spinal market, with an estimated value
of 10 billion dollars, is currently growing rapidly (+6.4% per year to 2020).
Long dominated by established players in the spinal field offering a large but
relatively uninnovative range of products, the market today has been shaken up
by the arrival of new challengers such as Spineart.
in 2005, Spineart creates and develops disruptive technologies for surgeons and
patients (new forms of implants, different methods of implantation, innovative
materials etc.). A pioneer in its field, the company has long been experiencing
rapid growth which enabled it to generate a global turnover of 34 million euros
perfectly fits the profile of the companies that Bryan, Garnier & Co advises:
it is a European company, in the healthcare sector, experiencing fast growth in
a flourishing market”, states Hervé Ronin, Partner at Bryan, Garnier & Co.
The bank has in fact followed Spineart for several years and accompanied the
founders, managers and shareholders, throughout the fundraising process,
alongside Société Générale, who also advised on this transaction. After having
approached several investors, Bryan, Garnier & Co, Société Générale and
Spineart selected Gimv, a healthcare specialist investor, to be the partner of
choice to accompany the company’s ambitions.
Jérôme Lévieux and
Stéphane Mugnier-Jacob, co-founders and co-CEOs of Spineart commented: “Bryan Garnier’s team demonstrated strong
commitment throughout the process. Their deep expertise and understanding of
our business and industries has been instrumental in raising interest from investors, leading to the successful completion of this transaction.”
Hervé Ronin, Partner
at Bryan, Garnier & Co added: “We are
delighted to support Spineart, one of the most dynamic orthopaedic companies in
Europe, in this financing round. This transaction illustrates once more the
unique ability of Bryan, Garnier & Co to support European growth companies
in the healthcare sector, in their various financial needs”.
Spineart: Jérôme Lévieux, Stéphane Mugnier-Jacob, Jérôme Ventura
Bryan, Garnier & Co: Hervé Ronin, Jean de Pracomtal
About Spineart (www.spineart.com)
Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients. Spineart is a pioneer in its field, having introduced unique patented and clinically validated technologies in the fields of Minimally Invasive Surgery, Motion Preservation, Fusion, Biologics, and Fractures Treatment. Spineart markets a complete portfolio combining traceable barcoded sterile packed implants with compact instrument sets, thus proudly promoting greater safety, cost-efficiency, and compliance at the hospital. Founded in 2005, Spineart addresses 7 countries (of which the US) via direct sales and 39 countries through distributors across EMEA, Asia and Latin America.
About Bryan, Garnier & Co (www.bryangarnier.com)
Bryan, Garnier & Co is one of the leading
independent investment banks specialized in European healthcare growth
companies. We have a dedicated franchise of 20 senior professionals including
investment bankers, equity research analysts and institutional sales
professionals. Our team covers the key market sub-categories such as :
biotechnology, large cap and specialty pharmaceuticals, life science tools,
medical technology, diagnostics, healthcare information technology and
In 2015, Bryan, Garnier & Co completed over 10 transactions for European healthcare growth companies, raising a total of approximately $1 billion. We top the European healthcare fundraising league tables and are the number one Investment bank for fund raising on Euronext. In the past 24 months, Bryan, Garnier & Co was the most active investment bank involved in the IPO and follow-on of European healthcare growth companies on the US Nasdaq advising companies such as LDR, DBV Technologies as well as Galapagos.
Bryan, Garnier & Co is authorized and regulated by
the Financial Conduct Authority (FCA) in the United Kingdom, and is member of
London Stock Exchange and Euronext, Alternext Listing Sponsor, and is
active in all European capital markets.